Exhibit 99.1

 

BIOLASE Reports First Quarter 2020 Financial Results

IRVINE, Calif., May 7, 2020

– BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the first quarter ended March 31, 2020.

 

“Our go-to-market strategy was demonstrating meaningful progress prior to the COVID-19 pandemic, reflecting the changes we made throughout 2019 to better align our business and operating infrastructure,” said Todd Norbe, President and Chief Executive Officer. “However, we  had to adjust our operations in response to the closure of most dental offices during the second half of the quarter, and this business disruption had a significant negative impact on our financial results, as we sold a limited number of lasers in March, which is historically our strongest month of the quarter.  In an effort to maintain our presence with key constituencies to preserve these revenue opportunities, we quickly pivoted to increasing the number of online educational forums to showcase our industry-leading products, which have been extremely well attended.  Based on the enthusiasm and positive feedback received, we are hopeful that these educational events will result in additional sales leads that we can capitalize on once dentists resume their normal business practices.

“Additionally, we recently announced a partnership with an intensive care unit (ICU) equipment manufacturer to supply ICU-grade portable ventilators through BIOLASE’s FDA-registered manufacturing facility. We have experienced a steady rate of activity and to date we have received over $14 million in orders.”

 

2020 First Quarter Financial Results

Net revenue for the first quarter of 2020 was $4.7 million, a decrease of 54%, compared to net revenue of $10.3 million for first quarter of 2019. U.S. laser revenue was $1.0 million for the first quarter of 2020, a 62% decrease compared to U.S. laser revenue of $2.6 million for the first quarter of 2019. U.S. consumables and other revenue for the first quarter of 2020, which consists of revenue from consumable products such as disposable tips, decreased 28% compared to the first quarter of 2019. Outside the U.S., laser revenue declined 68% to $1.1 million for the first quarter of 2020 compared to $3.4 million for the first quarter of 2019 and consumables and other revenue decreased 28% year over year.

Gross margin for the first quarter of 2020 was 28%, compared to 34% for first quarter of 2019. The lower gross margin reflects the impact of the decline in revenues relative to our fixed costs. Total operating expenses were $6.7 million for the first quarter of 2020 compared to $7.9 million for the first quarter of 2019, a decrease of over 15%. Operating loss for the first quarter of 2020, was $5.4 million, compared to an operating loss of $4.4 million in the first quarter of 2019, an increase of 23% year over year. Net loss for the first quarter of 2020 was $6.0 million, or $0.19 per share, compared to a net loss of $4.9 million, or $0.23 per share, for the first quarter of 2019.

Cash, cash equivalents, and restricted cash totaled $1.8 million as of March 31, 2020.

After the end of the first quarter, BIOLASE applied for and received a $3.0 million loan from the Paycheck Protection Program (“PPP”). The PPP was initiated to help small businesses defined as those businesses in the US with under 500 employees. BIOLASE has approximately 150 employees and is well under the 500 employee defined maximum. In addition, BIOLASE believes


the PPP was intended to help small businesses like BIOLASE mitigate the impact of significant lost business during the COVID-19 economic shutdown and to help keep as many people employed as possible. Given the existing market environment, BIOLASE did not believe that it could access public equity markets to raise cash to help make up for the significant lost revenue BIOLASE experienced during the first quarter of 2020 and likely to continue into the second quarter of 2020.

Additionally, both BIOLASE’s President and Chief Executive Office and Chief Financial Officer took temporary 40% salary cuts in connection with COVID-19 cost reduction measures.

 

Use of Non-GAAP Measures

The Reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's Adjusted EBITDA and Adjusted EBITDA per share.

Adjusted EBITDA for the first quarter of 2020 was $3.6 million, or $0.11 per share, compared with Adjusted EBITDA of $3.2 million, or $0.15 per share, for the first quarter of 2019.

 

Conference Call Information

BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the first quarter ended March 31, 2020, and to answer questions. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 800-353-6461. For international participants outside the U.S./Canada, the dial-in number is 334-323-0501. For all callers, refer to the Conference ID 6799229. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see “Investor Events”.

An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

 

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.  BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately patented 261 and 52 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.



Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, predictions, or expectations regarding BIOLASE’s revenue during the second quarter of 2020. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith,  adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

BIOLASE, Inc.

John R. Beaver, Executive Vice President and Chief Financial Officer

833-BIOLASE

jbeaver@biolase.com

or

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754

mpolyviou@evcgroup.com / tkehrli@evcgroup.com

Tables to Follow


 

BIOLASE, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

(Unaudited)

 

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2020

 

 

2019

 

Net revenue

 

 

 

4,783

 

 

 

 

10,326

 

Cost of revenue

 

 

 

3,430

 

 

 

 

6,804

 

Gross profit

 

 

 

1,353

 

 

 

 

3,522

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

 

2,704

 

 

 

 

3,879

 

General and administrative

 

 

 

3,010

 

 

 

 

2,393

 

Engineering and development

 

 

 

991

 

 

 

 

1,424

 

Change in fair value of patent litigation settlement liability

 

 

 

 

 

 

 

190

 

Total operating expenses

 

 

 

6,705

 

 

 

 

7,886

 

Loss from operations

 

 

 

(5,352

)

 

 

 

(4,364

)

Loss on foreign currency transactions

 

 

 

84

 

 

 

 

43

 

Interest expense, net

 

 

 

589

 

 

 

 

478

 

Non-operating loss

 

 

 

673

 

 

 

 

521

 

Loss before income tax provision

 

 

 

(6,025

)

 

 

 

(4,885

)

Income tax provision

 

 

 

(19

)

 

 

 

15

 

Net loss

 

$

 

(6,006

)

 

$

 

(4,900

)

 

 

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

Basic

 

$

 

(0.19

)

 

$

 

(0.23

)

Diluted

 

$

 

(0.19

)

 

$

 

(0.23

)

Shares used in the calculation of net loss per share:

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

31,509

 

 

 

 

21,134

 

Diluted

 

 

 

31,509

 

 

 

 

21,134

 

 


 

BIOLASE, INC.

 

CONSOLIDATED BALANCE SHEETS

 

(In thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

 

December 31,

 

 

 

2020

 

 

2019

 

 

 

(Unaudited)

 

 

(Audited)

 

ASSETS

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

1,511

 

 

$

 

5,789

 

Restricted cash

 

 

 

312

 

 

 

 

312

 

Accounts receivable, less allowance of $3,560 and $2,531 in 2020          and 2019, respectively

 

 

 

4,749

 

 

 

 

8,760

 

Inventory

 

 

 

12,192

 

 

 

 

10,995

 

Prepaid expenses and other current assets

 

 

 

1,205

 

 

 

 

1,163

 

Total current assets

 

 

 

19,969

 

 

 

 

27,019

 

Property, plant and equipment, net

 

 

 

1,017

 

 

 

 

1,193

 

Goodwill

 

 

 

2,926

 

 

 

 

2,926

 

Right of use asset

 

 

 

135

 

 

 

 

276

 

Other assets

 

 

 

484

 

 

 

 

433

 

Total assets

 

$

 

24,531

 

 

$

 

31,847

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES, REDEEMABLE PREFERRED STOCK AND

STOCKHOLDERS’ (DEFICIT) EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

 

4,056

 

 

$

 

5,332

 

Accrued liabilities

 

 

 

4,079

 

 

 

 

4,744

 

Deferred revenue, current portion

 

 

 

1,982

 

 

 

 

2,237

 

Term loan (net of discount)

 

 

 

13,562

 

 

 

 

13,466

 

Total current liabilities

 

 

 

23,679

 

 

 

 

25,779

 

Deferred revenue

 

 

 

390

 

 

 

 

358

 

Warranty accrual

 

 

 

246

 

 

 

 

245

 

Other liabilities

 

 

 

1,107

 

 

 

 

1,123

 

Total liabilities

 

 

 

25,422

 

 

 

 

27,505

 

Redeemable preferred stock:

 

 

 

 

 

 

 

 

 

 

Preferred stock, par value $0.001 per share

 

$

 

3,965

 

 

$

 

3,965

 

Total redeemable preferred stock

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

Common stock, par value $0.001 per share

 

 

 

32

 

 

 

 

31

 

Additional paid-in capital

 

 

 

236,384

 

 

 

 

235,594

 

Accumulated other comprehensive loss

 

 

 

(719

)

 

 

 

(701

)

Accumulated deficit

 

 

 

(240,553

)

 

 

 

(234,547

)

Total stockholders’ (deficit) equity

 

 

 

(4,856

)

 

 

 

377

 

Total liabilities, redeemable preferred stock and stockholders’ (deficit) equity

 

$

 

24,531

 

 

$

 

31,847

 

 


 

BIOLASE, INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(Unaudited, in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2020

 

 

2019

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(6,006

)

 

$

(4,900

)

Adjustments to reconcile net loss to net cash and cash equivalents

   used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

177

 

 

 

258

 

Provision for bad debts, net

 

 

987

 

 

 

19

 

Amortization of debt discounts

 

 

46

 

 

 

38

 

Amortization of debt issuance costs

 

 

50

 

 

 

49

 

Stock-based compensation

 

 

719

 

 

 

757

 

Deferred income taxes

 

 

(32

)

 

 

(5

)

Earned interest income, net

 

 

 

 

 

(1

)

Change in fair value of patent litigation settlement liability

 

 

 

 

 

190

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

3,024

 

 

 

(650

)

Inventory

 

 

(1,197

)

 

 

225

 

Prepaid expenses and other current assets

 

 

(142

)

 

 

463

 

Accounts payable and accrued liabilities

 

 

(1,541

)

 

 

(1,514

)

Deferred revenue

 

 

(219

)

 

 

37

 

Net cash and cash equivalents used in operating activities

 

 

(4,134

)

 

 

(5,034

)

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

 

Purchases of property, plant, and equipment

 

 

(9

)

 

 

(8

)

Net cash and cash equivalents used in investing activities

 

 

(9

)

 

 

(8

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

Payments of equity offering costs

 

 

(117

)

 

 

 

Proceeds from exercise of stock options

 

 

 

 

 

3

 

Net cash and cash equivalents (used in) provided by financing activities

 

 

(117

)

 

 

3

 

Effect of exchange rate changes

 

 

(18

)

 

 

(49

)

Decrease in cash, cash equivalents and restricted cash

 

 

(4,278

)

 

 

(5,088

)

Cash, cash equivalents and restricted cash, beginning of period

 

 

6,101

 

 

 

8,356

 

Cash, cash equivalents and restricted cash, end of period

 

$

1,823

 

 

$

3,268

 

Supplemental cash flow disclosure:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

485

 

 

$

430

 

Cash paid for income taxes

 

$

28

 

 

$

31

 

Cash paid for operating leases

 

$

192

 

 

$

189

 

Non-cash accrual for capital expenditures

 

$

7

 

 

$

24

 

Non-cash right-of-use assets obtained in exchange for lease

   obligation

 

$

 

 

$

824

 

 


Non-GAAP Disclosure

In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. (“GAAP”), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company’s ongoing core operating performance than their GAAP equivalents. In 2019, the Company revised its non-GAAP financial measures to include the change in allowance for doubtful accounts in an effort to better align its Adjusted EBITDA with its loan covenants and how management evaluates business performance.

Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, change in fair value of patent litigation settlement liability, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company’s core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

 

BIOLASE, INC.

 

Reconciliation of GAAP Net Loss to Adjusted EBITDA

 

(Unaudited)

 

(In thousands, except per share data)

 

 

 

 

 

Three Months Ended

 

 

March 31,

 

 

2020

 

 

2019

 

GAAP net loss attributable to common stockholders

$

 

(6,006

)

 

$

 

(4,900

)

Deemed dividend on convertible preferred stock

 

 

 

 

 

 

 

GAAP net loss

$

 

(6,006

)

 

$

 

(4,900

)

Adjustments:

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

589

 

 

 

 

478

 

Income tax provision

 

 

(19

)

 

 

 

15

 

Depreciation and amortization

 

 

177

 

 

 

 

258

 

Change in fair value of patent litigation settlement liability

 

 

 

 

 

 

190

 

Change in allowance for doubtful accounts

 

 

987

 

 

 

 

 

Stock-based compensation

 

 

719

 

 

 

 

757

 

Adjusted EBITDA

$

 

(3,553

)

 

$

 

(3,202

)

 

 

 

 

 

 

 

 

 

 

GAAP net loss attributable to common stockholders

   per share, basic and diluted

$

 

(0.19

)

 

$

 

(0.23

)

Deemed dividend on convertible preferred stock

 

 

 

 

 

 

 

GAAP net loss per share, basic and diluted

$

 

(0.19

)

 

$

 

(0.23

)

Adjustments:

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

0.02

 

 

 

 

0.02

 

Income tax provision

 

 

 

 

 

 

 

Depreciation and amortization

 

 

0.01

 

 

 

 

0.01

 

Change in fair value of patent litigation settlement liability

 

 

 

 

 

 

0.01

 

Change in allowance for doubtful accounts

 

 

0.03

 

 

 

 

 

Stock-based compensation

 

 

0.02

 

 

 

 

0.04

 

Adjusted EBITDA per share, basic and diluted

$

 

(0.11

)

 

$

 

(0.15

)

 

View differences made from one to another to evaluate Biolase, Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biolase, Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account